The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Open accessAbstract
BACKGROUND A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial lung disease (SSc-ILD) in a phase 3 trial to investigate the safety and efficacy of tocilizumab, an anti-interleukin-6 receptor antibody, in the treatment of systemic sclerosis. METHODS In this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, participants were recruited from 75 sites in 20 countries across Europe, North America, Latin America, and Japan. Adults with diffuse cutaneous systemic sclerosis for 60 months or less and a modified Rodnan skin score (mRSS) of 10-35 at screening were randomly assigned (1:1) with a voice-web-response system to receive subcutaneous tocilizumab 162 mg or placebo weekly for 48 weeks, stratified by IL-6 levels; participants and investigators were masked to treatment group. The primary endpoint was the difference in change from baseline to week 48 in mRSS. Percentage of predicted forced vital capacity (FVC% predicted) at week 48, time to treatment failure, and patient-reported and physician-reported outcomes were secondary endpoints. This trial is registered with ClinicalTrials.gov (number NCT02453256) and is closed to accrual. FINDINGS Between Nov 20, 2015, and Feb 14, 2017, 210 individuals were randomly assigned to receive tocilizumab (n=104) or placebo (n=106). In the intention-to-treat population, least squares mean [LSM] change from baseline to week 48 in mRSS was -6·14 for tocilizumab and -4·41 for placebo (adjusted difference -1·73 [95% CI -3·78 to 0·32]; p=0·10). The shift in distribution of change from baseline in FVC% predicted at week 48 favoured tocilizumab (van Elteren nominal p=0·002 vs placebo), with a difference in LSM of 4·2 (95% CI 2·0-6·4; nominal p=0·0002), as did time to treatment failure (hazard ratio 0·63 [95% CI 0·37-1·06]; nominal p=0·08). Change in LSM from baseline to week 48 in Health Assessment Questionnaire-Disability Index and in patient-global and physician-global visual analogue scale assessments did not differ between tocilizumab and placebo. In the safety set, infections were the most common adverse events (54 [52%] of 104 participants in the tocilizumab group, 53 [50%] of 106 in the placebo group). Serious adverse events were reported in 13 participants treated with tocilizumab and 18 with placebo, primarily infections (three events, eight events) and cardiac events (two events, seven events). INTERPRETATION The primary skin fibrosis endpoint was not met. Findings for the secondary endpoint of FVC% predicted indicate that tocilizumab might preserve lung function in people with early SSc-ILD and elevated acute-phase reactants. Safety was consistent with the known profile of tocilizumab. FUNDING F Hoffmann-La Roche Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
van den Hoogen, F., Khanna, D., Fransen, J., Johnson, S. R., Baron, M., Tyndall, A., Matucci-Cerinic, M., Naden, R. P., Medsger, T. A., Carreira, P. E., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204424 · Cited by 2,886
Self-citationDenton, C. P., & Khanna, D. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30933-9 · Cited by 2,212
Self-citationCyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationNintedanib for systemic sclerosis–associated interstitial lung disease
Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903076 · Cited by 1,647
Self-citationUpdate of EULAR recommendations for the treatment of systemic sclerosis
Kowal-Bielecka, O., Fransen, J., Avouac, J., Becker, M., Kulak, A., Allanore, Y., Distler, O., Clements, P., Cutolo, M., Czirjak, L., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209909 · Cited by 1,104
Self-citationMapping and predicting mortality from systemic sclerosis
Elhai, M., Meune, C., Boubaya, M., Avouac, J., Hachulla, E., Balbir-Gurman, A., Riemekasten, G., Airò, P., Joven, B., Vettori, S., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211448 · Cited by 691
Self-citationKhanna, D., Denton, C. P., Jahreis, A., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00232-4 · Cited by 683
Self-citationStandardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis
Khanna, D., Furst, D. E., Clements, P. J., Allanore, Y., Baron, M., Czirjak, L., Distler, O., Foeldvari, I., Kuwana, M., Matucci-Cerinic, M., et al. (2017) · Journal of Scleroderma and Related Disorders · doi:10.5301/jsrd.5000231 · Cited by 541
Self-citation
Cited by
Volkmann, E. R., Andréasson, K., & Smith, V. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01692-0 · Cited by 616
Self-citationInterstitial Lung Disease: A Review
Maher, T. M. (2024) · JAMA · doi:10.1001/jama.2024.3669 · Cited by 388
EULAR recommendations for the treatment of systemic sclerosis: 2023 update
Del Galdo, F., Lescoat, A., Conaghan, P. G., Bertoldo, E., Čolić, J., Santiago, T., Suliman, Y. A., Matucci-Cerinic, M., Gabrielli, A., Distler, O., et al. (2025) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2024-226430 · Cited by 258
Self-citationImmune cell dysregulation as a mediator of fibrosis in systemic sclerosis
Fang, D., Chen, B., Lescoat, A., Khanna, D., & Mu, R. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00864-7 · Cited by 84
Self-citation
Metadata
- Authors
- Khanna, D., Lin, C. J. F., Furst, D. E., Goldin, J., Kim, G., Kuwana, M., Allanore, Y., Matucci-Cerinic, M., Distler, O., Shima, Y., van Laar, J. M., Spotswood, H., Wagner, B., Siegel, J., Jahreis, A., Denton, C. P., Lucero, E., Pons-Estel, B., Rivero, M., Tate, G., Smith, V., De Langhe, E., Rashkov, R., Batalov, A., Goranov, I., Stoilov, R., Dunne, J., Johnson, S. R., Pope, J. E., Martinović Kaliterna, D., Mogensen, M., Olesen, A. B., Allanore, Y., Henes, J. C., Müller-Ladner, U., Riemekasten, G., Skapenko, A., Vlachoyiannopoulos, P., Kiss, E., Minier, T., Beretta, L., Gremese, E., Matucci-Cerinic, M., Valentini, G., Asano, Y., Atsumi, T., Ihn, H., Ishii, T., Ishikawa, O., Kuwana, M., Shima, Y., Takahashi, H., Takehara, K., Tanaka, Y., Yamasaki, Y., Bukauskiene, L., Butrimiene, I., Medrano Ramirez, G., Ramos-Remus, C., Sofia Rodriguez Reyna, T., de Vries-Bouwstra, J., van Laar, J. M., Batko, B., Jeka, S., Kucharz, E., Majdan, M., Olesinska, M., Smolenska, Z., Alves, J., Santos, M., Mihai, C. M., Rednic, S., Castellvi Barranco, I., Lopez Longo, F. J., Simeon Aznar, C., Carreira, P., Distler, O., Walker, U. A., Derrett-Smith, E., Griffiths, B., McKay, N., Denton, C. P., Aelion, J., Borofsky, M., Fleischmann, R., Forstot, J. Z., Furst, D. E., Kafaja, S., Khan, M. F., Khanna, D., Kohen, M. D., Martin, R. W., Mendoza-Ballesteros, F., Nami, A., Pang, S., Rios, G., Simms, R., Sullivan, K. M., & Steen, V. D.
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 8
- Issue
- 10
- Pages
- 963-974
- ISSN
- 2213-2600 (ISSN-L)
- OpenAlex
- W3081624185
- Cited by
- 662
- References
- 32
- FWCI
- 48.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s2213-2600(20)30318-0
- The paper
- Khanna, D., Lin, C. J. F., Furst, D. E., Goldin, J., Kim, G., Kuwana, M., Allanore, Y., Matucci-Cerinic, M., Distler, O., Shima, Y., van Laar, J. M., Spotswood, H., Wagner, B., Siegel, J., Jahreis, A., Denton, C. P., Lucero, E., Pons-Estel, B., Rivero, M., . . . Steen, V. D. (2020). Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(20)30318-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.